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Abstract
Introduction: Bone marrow-derived mesenchymal stromal cells (MSCs) have been intensely studied for the
purpose of developing solutions for clinical tissue engineering. Autologous MSCs can potentially be used to
replace tissue defects, but the procedure also carries risks such as immunization and xenogeneic infection.
Replacement of the commonly used fetal calf serum (FCS) with human platelet lysate and plasma (PLP) to
support cell growth may reduce some of these risks. Altered media could, however, influence stem cell
differentiation and we address this experimentally.
Methods: We examined human MSC differentiation into the osteoblast lineage using in vitro two- and
three-dimensional cultures with PLP or FCS as cell culture medium supplements. Differentiation was followed
by quantitative polymerase chain reaction, and alkaline phosphatase activity, matrix formation and matrix
calcium content were quantified.
Results: Three-dimensional culture, where human MSCs were grown on collagen sponges, markedly stimulated
osteoblast differentiation; a fourfold increase in calcium deposition could be observed in both PLP and FCS
groups. PLP-grown cells showed robust osteogenic differentiation both in two- and three-dimensional MSC
cultures. The calcium content of the matrix in the two-dimensional PLP group at day 14 was 2.2-fold higher in
comparison to the FCS group (p < 0.0001), and at day 21 it was still 1.3-fold higher (p < 0.001), suggesting earlier
calcium accumulation to the matrix in the PLP group. This was supported by stronger Alizarin Red staining in
the PLP group at day 14. In two-dimesional PLP cultures, cellular proliferation appeared to decrease during later
stages of differentiation, while in the FCS group the number of cells increased throughout the experiment. In
three-dimensional experiments, the PLP and FCS groups behaved more congruently, except for the alkaline
phosphatase activity and mRNA levels which were markedly increased by PLP.
Conclusions: Human PLP was at least equal to FCS in supporting osteogenic differentiation of human MSCs in
two- and three-dimensional conditions; however, proliferation was inferior. As PLP is free of animal components,
and thus represents reduced risk for xenogeneic infection, its use for human MSC-induced bone repair in the
clinic by the three-dimensional live implants presented here appears a promising therapy option.
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Introduction
Mesenchymal stromal cells (MSCs) are multipotent pro-
genitor cells that can be isolated from bone marrow, adi-
pose tissue, and other mesenchymal tissues. They can be
differentiated into bone, fat, cartilage, tendon, and muscle
[1]. These properties make MSCs an attractive agent for
regenerative medicine and especially for reconstructive
surgery in repair of bone defects [2–4]. MSCs also possess
immunosuppressive properties and have been used for the
treatment of acute graft versus host disease [5]. However,
the risks involved in cell expansion for clinical bone repair
still require careful evaluation. A number of preliminary
studies indicate that local and systemic administration of
autologous MSCs is safe [6–8]. To date, no serious com-
plications such as tumorigenesis have been reported [9].
Fetal calf serum (FCS) has been widely used in osteogenic
MSC cultures. Its xenogeneic origin poses two potential
problems: the risk of xenogeneic infections and the risk of
adverse immune reactions. Use of animal-derived cell cul-
ture materials contaminates both the cell surface and
intracellular structures with xenoantigens [10, 11]. Ex-
posure to these antigens may lead to immune reactions
and graft rejection [12]. Use of animal-derived cell
culture supplements introduces the risk of transferring
bovine spongiform encephalopathy and other yet un-
known zoonoses [13, 14]. Therefore, for clinical pur-
poses, it is essential to find culture methods enabling
osteogenic differentiation of MSCs that do not utilize
animal-derived materials.
The combination of platelet lysate and plasma (PLP)
supports the growth and proliferation of MSCs [15]. PLP
is easily obtained from normal human blood. PLP con-
tains growth factors, such as platelet-derived growth fac-
tor, transforming growth factors β1 and β2, insulin-like
growth factor, epidermal growth factor, and endothelial
cell growth factor, which all support bone healing. This
makes PLP a promising material for human osteogenic
MSC cultures [16]. However, it is uncertain whether
PLP-grown MSCs display osteogenic potential compar-
able to cells grown using the standard FCS-based culture
media [17–19].
It is envisioned that the repair of bone defects requires
the implantation of the therapeutic cells into patients
within three-dimensional (3D) cell matrices. The matrix
must both support the growth of MSCs and the differenti-
ation of the osteoblast phenotype, and it must be biocom-
patible with bone healing [20]. Several different scaffold
materials have been employed in animal models [21–23].
In our study, we have used a collagen sponge scaffold
(Spongostan®; Ferrosan, Soeborg, Denmark) which is
already in clinical use for surgical hemostasis. It has previ-
ously been used as a cell culture scaffold to repair bone
defects in congenital pseudoarthrosis [7] and as a 3D scaf-
fold for autologous chondrocyte transplantation [24].
In this paper, we have compared the osteogenic differen-
tiation potential of human MSCs that have been grown in
FCS and PLP. After establishing the culture methods in a
two-dimensional (2D) cell culture system, we plated the
cells into Spongostan collagen matrix. We used several
different assays to follow the osteogenic differentiation
and to compare the FCS and PLP cultures against each
other in both 2D and 3D cultures. We demonstrate that
MSCs cultured without animal-derived components are
capable of osteogenic differentiation and have thus clinical
potential for bone repair.
Methods
Cell culture
Human MSCs were obtained from bone marrow aspi-
rates from healthy volunteer donors aged 20–30 years
after signed informed consent. The protocol was ap-
proved by the Ethics committee of the Helsinki Uni-
versity Central Hospital, Finland. Bone marrow (20 ml)
was aspirated under local anesthesia from the posterior
iliac crest into heparinized tubes. Mononuclear cells
were isolated with a Ficoll-Paque (Pharmacia, Uppsala,
Sweden) density gradient centrifugation and plated at
the density of 4 × 105 cells/cm2 in either PLP or FCS
expansion medium. The cells were kept in either FCS
or PLP medium throughout the experiments. After
about 3 days of culture, the plates were washed thor-
oughly with phosphate-buffered saline (PBS) to remove
nonadherent cells. The medium was changed every 3
to 4 days. After 3 weeks of culture, the primary cul-
tures were passaged at 103 cells/cm2. The cells were
thereafter passaged always when they reached 80 %
confluency. A standard panel of surface markers was
used to characterize the cells (see Additional file 1).
Differentiation assays were used to demonstrate adipo-
genic and osteogenic differentiation potential (see
Additional file 1).
Preparation of expansion media
The basic medium consisted of low-glucose Dulbecco’s
modified Eagle’s medium supplemented with 100 U/ml
penicillin, 100 μg/ml streptomycin (EuroClone, S.p.A.
P.IVA, Italy) and 2 mM L-glutamine (EuroClone). FCS
expansion medium was made from basic medium supple-
mented with 10 % FCS (tested for its ability to support
MSC expansion; StemCell Technologies, Vancouver, BC,
Canada).
PLP was obtained by pooling four platelet units con-
taining approximately 300 × 109 platelets from the local
blood bank (Finnish Red Cross Blood Service, Helsinki,
Finland). Platelets were centrifuged, suspended in AB
plasma (Octaplas, Finnish Red Cross Blood Service)
and frozen. The platelets underwent five rapid freeze–
thaw cycles. Before use, the ability of the platelet lysate to
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support MSC expansion was tested using FCS expansion
medium as a reference. The PLP expansion medium con-
sisted of 2.5 % AB-plasma (Octaplas), 0.5 % platelet lysate
(final concentration approximately 0.8 × 108 platelets/ml)
and 40 IU/ml heparin (Sigma, St. Louis, MO, USA) added
to the basic medium.
Osteogenic differentiation of MSCs
Osteogenic differentiation medium consisted of either
FCS or PLP expansion medium supplemented with
10 mM β-glycerophosphate, 0.1 μM dexamethasone, and
200 μM ascorbic acid-2-phosphate (all from Sigma). FCS
or PLP expansion medium alone without these supple-
ments was used for control samples.
For 2D cultures, cells from passage two were plated at
5 × 103/cm2 in expansion medium. When they reached
70 % confluence, they were changed into a differenti-
ation medium, and cultured further up to 28 days.
For 3D cultures, 25 × 103 cells from passage two in 75 μl
expansion medium were pipetted into 7 × 7 × 10 mm
Spongostan® collagen scaffold (Ferrosan) in 24-well plates.
After an adhesion period of 6 hours, 1 ml expansion
medium was added to each well. The following day, the
cells were changed into differentiation medium and cul-
tured up to 28 days.
The increase in cell number during the osteogenic
differentiation was assessed by harvesting the 2D cul-
tured cells with trypsin-EDTA and counting them with
a Coulter cell counter. Cells cultured in the 3D system
were harvested by dissolving the collagen scaffolds with
collagenase B (1 mg/ml; Roche, Mannheim, Germany)
and counted thereafter as above.
Assays for osteogenic differentiation
To detect alkaline phosphatase (ALP) activity, we used
the SensoLyte™ pNPP Alkaline Phosphatase Assay Kit
Colorimetric (Anaspec, Fremont, CA, USA). Cells from
passage three were plated in six-well plates (2D cultures)
or in collagen scaffolds (3D) and grown up to 21 days.
To recover the cells, the plates were washed twice and
harvested in assay buffer with 1 % Tx-100. For 3D cul-
tures, the collagen scaffolds were first dissolved with
1 mg/ml collagenase B, after which the cells were washed
twice and suspended in assay buffer with 1 % Tx-100. The
cell suspension was collected into Eppendorf tubes and
incubated for 10 minutes at 4 °C under agitation. Aliquots
of the extract were mixed with para-nitrophenyl phos-
phate (pNPP) substrate solution and the results were read
spectrophotometrically at 405 nm.
To analyze the deposition of a collagenous and min-
eralized matrix in 2D cultures, the cells from passage
one were plated in 24-well plates and cultured up to
21 days. The cell cultures were washed with PBS and
fixed in 10 % paraformaldehyde (PFA) for 5 minutes at
room temperature. In order to detect collagenous matrix
deposition, the cell cultures were stained with 1 % Sirius
Red (Direct Red 80; Sigma) in saturated picric acid for
1 hour, after which the plates were washed extensively
with 0.5 % acetic acid. The plates were dried and scanned
with the Epson Perfection V500 Photo Scanner (Epson
Inc., Long Beach, CA, USA) and converted into binary
images with the Adobe Photoshop CS3 Extended program
(Adobe systems Inc., San Jose, CA, USA). The optical dens-
ity (OD) of the Sirius Red-stained cultures was measured
with the public domain ImageJ software (http://imagej.net/
Welcome) and the values were calibrated according to the
ImageJ instructions. To detect mineralized matrix, the
matrix was stained with 2 % Alizarin Red S (Sigma) for
30 minutes after which the plates were washed extensively
with tap water. The plates were dried and scanned and
optical densities were measured as above.
Cells cultured in 3D matrices from passage three were
fixed with 4 % PFA for 30 minutes, frozen in liquid nitro-
gen and mounted into Tissue-Tek OCT compound
(Sakura Finetek, Torrance, CA, USA). Cryostat sections
(6 μm) were stained with hematoxylin and eosin to
visualize the general structure of the 3D matrix. Other
sections were incubated with Alizarin Red for 30 minutes,
washed thoroughly with tap water and photographed with
Olympus Provis AX70 (Olympus, Tokyo, Japan).
In order to measure calcium deposition in the cell cul-
tures from passage three, calcium was extracted in 40 μl
(2D cultures) or 200 μl (3D cultures) 0.5 M HCl at 4 °C
for 24 hours. After clearing the extracts by centrifugation,
aliquots were mixed with an o-cresolphthalein complex-
one reagent (StanbioTotal Calcium LiquiColor, Boerne,
TX, USA) according to the manufacturer’s instructions.
The results were read spectrophotometrically at 550 nm.
Standard curves were included in each measurement.
Quantitative real-time polymerase chain reaction
For isolation of total RNA, the 3D cultures were first
disrupted using an ultrasound homogenizer. RNA was
isolated with TRIzol reagent (Invitrogen, Paisley, UK) ac-
cording to the manufacturer’s instructions from both 2D
and 3D cultured cells from passage three. First strand
cDNA was synthesized from 200 ng total RNA using the
Superscript enzyme (SuperScript® VILO™ cDNA Synthe-
sis Kit; Invitrogen). cDNA synthesis without sample and
without enzyme were used as negative controls. Quanti-
tative real-time polymerase chain reaction (RT-PCR) was
run in a LightCycler PCR machine using LightCycler
FastStart DNA Master SYBR Green I kit (Roche) twice
for each sample. Primers were designed with Primer3
(SourceForge, Roche, Mannheim, Germany), the se-
quences were searched using the National Center for
Biotechnology Information (NCBI) Entrez search sys-
tem, and sequence similarities using the NCBI Blastn
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program. Primer sequences used were 5′-GGTTTCAGT
GGTTTGGATGG-3′ (forward) and 5′- ATTGGCACCT
TTAGCACCAG-3′ (reverse) for collagen I α1 (COL1A1;
producing amplicon length of 396 bp); 5′- TCAACACC
AACGTGGCTAAG-3′ (forward) and 5′-CACAATGCCC
ACAGATTTCC-3′ (reverse) for ALP (356 bp); 5′-TCACA
CTCCTCGCCCTATTG-3′ (forward) and 5′- TCAGCCA
ACTCGTCACAGTC-3′ (reverse) for osteocalcin (OCN;
244 bp); 5′- TTACTGTCATGGCGGGTAAC-3′ (forward)
and 5′- ATGCGCCCTAAATCACTGAG-3′ (reverse) for
Runx2 (295 bp) and 5′-TCACCCACACTGTGCCCATC
TACGA-3′(forward) and 5′-CAGCGGAACCGCTCATT
GCCAATGG-3′ (reverse) for β-actin (295 bp).
To obtain the standard curve for quantitative PCR, the
genes of interest were amplified in a PCR reaction, ex-
tracted from the agarose gel and cloned into a pCRII-
TOPO vector (Invitrogen). After identification of the
plasmid by restriction enzyme analysis and sequencing,
its concentration was determined spectrophotometrically
and serial dilutions were prepared for quantitative PCR
analysis. The copy numbers of mRNA were determined in
duplicate for each culture condition and normalized
against 1 × 106 copies of the housekeeping β-actin gene.
Statistics
All differentiation experiments were carried out at least
three times using cells from different donors. Data are
expressed as mean ± standard deviation. Statistical signifi-
cance was evaluated using a two-tailed Student’s t-test and
<0.05 was considered significant.
Results
Characterization of MSCs
Cultured cells were shown to be MSCs by flow cytome-
try. Both PLP- and FCS-grown cells expressed com-
monly used MSC markers (CD73, CD90, and CD105),
but were negative for CD14, CD19, CD45, HLA-DR
(hematopoietic) and CD34 (hematopoietic/endothelial)
markers (Figure S1 in Additional file 2) [25]. The cells
were capable of osteogenic and adipogenic (Figure S2
in Additional file 2) differentiation.
Osteogenic differentiation in 2D cultures
Increase in cell number during differentiation in 2D cultures
To determine the rate of increase in cell number, cells
were harvested and counted during the 28-day differenti-
ation period (Fig. 1a). After plating, the number of PLP-
grown MSCs increased 3.5-fold by day 7 of culture, and
remained constant thereafter. The cells grown in FCS con-
tinued to proliferate throughout the experiment, resulting
in significantly more cells on day 28 (FCS differentiated,
140,460 ± 17,793 cells/well; PLP differentiated, 39,000 ±
4258 cells/well; p < 0.01). The growth in MSC number of
the control cultures paralleled that of the differentiating
cultures.
ALP activity in 2D cultures
Increase in ALP activity is known to accompany and
influence the osteogenic differentiation. Spectrophoto-
metric readings of ALP activity in PLP-grown cells
peaked on day 4 (PLP differentiated, 0.27 ± 0.01 ng/
Fig. 1 Cell proliferation and alkaline phosphatase (ALP) activity in two-dimensional (2D) cell culture. Cells were plated at the density of 5 × 103/
cm2, changed into osteogenic medium and cultured up to 28 days in 2D culture. a Cell enumeration was performed on days 1, 7, 14, 21 and 28.
b ALP activity was measured spectrophotometrically in each cell culture well at days 4, 7, 14 and 21. CTRL control, DIFF differentiation, FCS fetal
calf serum, ns not significant, PLP platelet lysate and plasma
Castrén et al. Stem Cell Research & Therapy  (2015) 6:167 Page 4 of 13
well; FCS differentiated 0.13 ± 0.02 ng/well; p < 0.01),
and declined thereafter (Fig. 1b). In FCS-grown cells,
ALP activity rose by day 7, and remained elevated
throughout the experiment (PLP differentiated versus
FCS differentiated on day 14 and 21, p < 0.001).
Quantitative PCR analysis for osteogenic markers in 2D
cultures
Osteogenic differentiation in 2D cultures was also exam-
ined by analyzing the expression of the Runx2, ALP,
Col1α1 and OCN genes using quantitative RT-PCR. In-
creased Runx2 levels were found on days 9 and 14 in FCS
but remained low in PLP cultures. In both conditions,
Runx2 levels rose until day 21 (Fig. 2a). ALP mRNA levels
increased steadily in both FCS and PLP cultures (Fig. 2b).
Col1α1 levels increased steeply until day 9 after which the
levels decreased in both FCS and PLP cultures (Fig. 2c).
OCN mRNA rose until day 21 (Fig. 2d). In FCS cultures,
elevated levels of OCN were seen from day 7 onwards,
whereas in PLP cultures elevated OCN expression was
seen only in late cultures.
Detection of osteogenic matrices in 2D cultures
First, we analyzed whether the differentiating cells depos-
ited a collagenous organic matrix, which is a prerequisite
for bone formation. The matrix was detected using Sirius
Red staining and quantified by measuring ODs. By day 14,
both PLP and FCS cultures displayed low amounts of
collagen matrix (Fig. 3a and c) which, using OD measure-
ments, was stronger in FCS- than in PLP-grown cultures
Fig. 2 Quantitative RT-PCR in two-dimensional (2D) cell culture. The cells were cultured in 2D osteogenic medium up to 21 days. Total RNA was
isolated and the expression of Runx2 (a), alkaline phosphatase (ALP) (b), collagen I α1 (Col1α1) (c), and osteocalcin (OCN) (d) was analyzed using
quantitative RT-PCR. DIFF differentiation, FCS fetal calf serum, PLP platelet lysate and plasma
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(p < 0.05). By day 21, the OD values had increased in all
cultures, with the FCS cultures still showing the strongest
staining (p < 0.05; Fig. 3b and c). However, the OD values
of PLP cultures were significantly higher (p < 0.001) than
those of the control cultures.
For detection of deposited mineralized matrix in the
differentiating MSC cultures, the cultures were stained
with Alizarin Red. By day 14 of differentiation, the PLP-
grown cells displayed more intensive Alizarin Red stain-
ing than the FCS cultures (p < 0.01; Fig. 4a and c). By
Fig. 3 Detection of collagenous matrix in 2D cell culture. Cells were cultured in 2D osteogenic conditions up to 21 days in FCS and PLP
culture media. At days a 14 and b 21, the cell cultures were fixed and stained with Sirius Red, after which they were dried and photographed.
c Thereafter, they were turned into binary images and optical densities were measured. CTRL control, DIFF differentiation, FCS fetal calf serum,
PLP platelet lysate and plasma
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day 21, both PLP- and FCS-grown cells showed evidence
of similarly rich mineralization (Fig. 4b and c). Quantita-
tive data, acquired by measuring OD values, confirmed
the visual impression (Fig. 4c).
Calcium deposition in 2D
Because Alizarin Red staining is somewhat unspecific,
we also quantified the calcium content of the deposited
matrix (Fig. 4d). The deposited calcium in each well was
measured spectrophotometrically. On day 7, the calcium
levels were essentially equal in all samples, indicating
that the deposition of calcium had not yet begun. On
day 14, calcium levels had increased in the differentiat-
ing cultures, with the PLP culture showing the strongest
response (PLP differentiated, 0.50 ± 0.02 μg/well; FCS
differentiated, 0.23 ± 0.01 μg/well; p < 0.0001). On day
21, the values had increased further, being still highest in
PLP cultures (PLP differentiated, 0.61 ± 0.03 μg/well;
FCS differentiated, 0.48 ± 0.02 μg/well; p < 0.001).
Osteogenic differentiation in 3D cultures
Increase in cell number during differentiation in 3D cultures
To analyze the cell numbers in the differentiating 3D
cultures, the matrices were dissolved with collagenase
and the cells were recovered and counted (Fig. 5a). In
PLP-differentiated cultures, the cell number peaked on
day 14 and declined somewhat thereafter, while FCS-
differentiated cultures peaked on day 21. Both differenti-
ating cultures reached a similar final cell number by day
28 (FCS differentiated, 73,993 ± 17,862 cells/well; PLP
differentiated, 78,047 ± 19,794 cells/well; nonsignificant),
while the cell counts in the control cultures remained
somewhat lower (26,640 ± 9041 cells/well in PLP control
and 40,613 ± 3820 cells/well in FCS control).
Alkaline phosphatase activity in 3D cultures
The pattern of ALP activity in 3D cultures differed sub-
stantially from that seen in 2D cultures. On day 7, the
PLP-grown differentiating cells showed slightly higher
levels of activity than the FCS-grown differentiating
cells; however, this was without a statistically significant
difference (PLP differentiated, 0.012 ± 0.003 ng/well; FCS
differentiated, 0.0067 ± 0.0002 ng/well; nonsignificant). On
day 14, the activity had further increased in PLP cultures,
Fig. 4 Detection of mineralized matrix and calcium deposition in
two-dimensional (2D) cell culture. Cells were cultured in 2D osteogenic
conditions up to 21 days in FCS and PLP culture media. On days a 14
and b 21, the cell cultures were fixed and stained with Alizarin Red,
after which they were dried and photographed. c Thereafter, they
were turned into binary images and optical densities were
measured. d Deposited calcium was dissolved in HCl and quantified
on days 7, 14 and 21 of culture using an o-cresolphthalein complexone
reagent using a standard curve as reference. CTRL control, DIFF
differentiation, FCS fetal calf serum, PLP platelet lysate and plasma
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being significantly higher than in FCS cultures (PLP differ-
entiated, 0.027 ± 0.006 ng/well; FCS differentiated, 0.0089
± 0.002 ng/well; p < 0.05) with no further increase in activ-
ity in either condition thereafter (Fig. 5b).
Quantitative PCR analysis for osteogenic markers in 3D
cultures
The mRNA profiles in 3D cultures also differed from
those seen in the 2D cultures. Runx2 mRNA levels peaked
on days 9 and 14 in FCS and PLP cultures, respectively
(Fig. 6a). ALP mRNA levels rose relatively early in FCS
cultures whereas a more marked rise in expression was
detected in PLP cultures at 21 days (Fig. 6b). OCN levels
peaked on day 9 in both FCS and PLP cultures, but were
higher in FCS cultures (Fig. 6c).
Detection of mineralized matrix and calcium deposition in
3D cultures
Sections of PLP and FCS 3D culture matrices stained with
Alizarin Red displayed nodules of mineralized matrix on
day 21 (not shown) and even more prominently on day 28
(Fig. 7a). No signs of mineralization were detected in the
control cultures.
The presence of mineralized matrices in the 3D cul-
tures was confirmed by analyzing the calcium content of
the wells (Fig. 7b). Very little calcium was detected on
day 7 in any of the culture conditions. On day 14,
calcium levels rose sharply in both osteogenic FCS and
PLP cultures, with FCS showing somewhat higher cal-
cium levels (FCS differentiated, 2.11 ± 0.07 μg/well; PLP
differentiated, 1.88 ± 0.12 μg/well; p < 0.01). Calcium
levels remained relatively constant thereafter with no
difference between PLP and FCS culture on day 28 (FCS
differentiated, 2.08 ± 0.08 μg/well; PLP differentiated,
2.04 ± 0.04 μg/well; nonsignificant). The calcium levels
remained low in control cultures without the osteogenic
supplements.
Discussion
MSCs are potential therapeutic agents for regenerative
medicine if they can be expanded in sufficient amounts,
grafted safely to the recipient, and induced to differentiate
and demonstrate efficacy in vivo. The necessity of using
animal-derived supplements for cell culture, carrying a
risk of disease transmission and patient immunization, has
been a major impediment for the application of cellular
therapies in clinical practice. To circumvent this problem,
we sought to substitute FCS with PLP in the MSC expan-
sion and differentiation medium. The only animal-derived
materials used for producing PLP cells were heparin and
the collagen sponge. Both are approved for human med-
ical use and pose little risk of transmission of xenogeneic
infections.
For therapeutic use, the cells must retain their osteo-
genic potential and they must be able to produce bone
matrix after implantation [26] or alternatively secrete
osteogenic or immunomodulatory paracrine factors,
which accelerate the natural bone healing.
A number of previous studies have shown that platelet
extracts produced by various methods may be utilized to
support osteogenic differentiation of MSCs [18, 19, 27–29].
In this report, we have studied the utility of PLP for ex-
pansion and differentiation of MSCs into osteoblasts in
2D and 3D cell cultures and compared their osteogenic
Fig. 5 Cell proliferation and alkaline phosphatase (ALP) activity in three-dimensional (3D) cell culture. Cells (25 × 103) were pipetted into 3D collagen
sponge scaffolds and cultured up to 28 days. a Cells were harvested by dissolving the collagen scaffolds with collagenase B and counted thereafter at
days 1, 7, 14, 21 and 28. b To measure ALP activity in 3D cultures, the collagen scaffolds were dissolved and cells were harvested. ALP activity
was measured spectrophotometrically at 405 nm at days 4, 7, 14 and 21. CTRL control, DIFF differentiation, FCS fetal calf serum, ns not significant, PLP
platelet lysate and plasma
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potential with similar cells cultured using the com-
monly used cell culture constituent FCS. We used cells
isolated from bone marrow aspirates of healthy donors
and set up parallel cultures in PLP and FCS from the
same donor. This was done to ensure that the cells in
PLP would not be exposed to FCS at any time during
culture. After expansion to the third passage, osteogenic
inductors were added to the cells to analyze osteogenic
differentiation. Parallel cultures are of importance because
the osteogenic capacity can greatly vary between donors.
The crucial parameters of osteogenic in vitro cultures are
sufficient cell proliferation, ALP activity, expression of
osteogenic markers and production of collagenous and
mineralized matrices.
In our study, the cell number in 2D PLP cultures was
smaller than in the FCS cultures throughout the in vitro
differentiation, and cell number even decreased in later
time points. One reason for this may be that PLP-grown
cells seem to detach more easily from culture plates
during the culture [30]. Recently we have shown that, in
long-term 2D culture (more than 100 days), FCS-grown
cells proliferate somewhat faster that MSCs grown in
PLP [31]. In 3D sponges, FCS and PLP supported prolif-
eration equally.
ALP expression and activity are prerequisites for osteo-
blast differentiation. ALP is also a ubiquitous marker
expressed by all osteoblasts from the mature osteoprogeni-
tor stage onwards [32]. In most of our experiments, ALP
activity was higher in FCS-grown cells, however, with some
variability between the donors. When mRNA levels of ALP
were normalized to the level of the β-actin housekeeping
gene, there was no difference in the ALP transcripts be-
tween PLP- and FCS-grown cells. Expression pattern of
Runx2, another early osteogenic marker, was also similar in
both FCS and PLP cultures.
Synthesis of a collagen matrix is required for the
deposition of a mineralized matrix. Both processes are
essential for treating bone defects. In order to analyze
matrix production, the 2D cultures were stained with
Sirius Red [33] and the expression of the main collagen
type present in bone tissue, collagen I, was quantified
with quantitative RT-PCR by measuring the Col1α1
gene. Sirius Red staining intensity was lower in PLP-
grown cultures than in FCS cultures, which may reflect
the lower cell number in PLP cultures. This is supported
by PCR expression studies, which were normalized to
the level of a housekeeping gene and revealed equal
levels of mRNA of Col1α1 per cell in PLP and FCS cul-
tures throughout the culture period.
In terms of mineralization, we found that PLP-cultured
cells possess robust osteogenic features, reflected in the
relatively high amount of mineralized matrix deposited at
14 day of the osteogenic differentiation. The level of
mineralization, as evaluated by both Alizarin Red staining
(Figs. 4a–c and 7a) and direct measurement of deposited
calcium (Figs. 4d and 7b) was higher in PLP than in the
traditional FCS cultures, in agreement with previous
Fig. 6 Quantitative RT-PCR in three-dimensional (3D) cell culture.
The cells were cultured in 3D osteogenic conditions up to 21 days.
Total RNA was isolated and the expression of Runx2 (a), alkaline
phosphatase (ALP) (b), and osteocalcin (OCN) (c) was analyzed using
quantitative RT-PCR. DIFF differentiation, FCS fetal calf serum, PLP
platelet lysate and plasma
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findings that mineralization starts earlier in PLP- than
FCS-grown cells [19]. On the other hand, mRNA levels of
OCN, a late osteogenic marker, was increased earlier in
FCS than PLP cultures (Fig. 2d). OCN is expressed in
postproliferative osteoblasts and appears concomitantly
with mineralization but there is a heterogeneity between
the donors [34]. Our results suggest that strong calcium
deposition can be initiated in PLP cultures even though
OCN levels are low in early cultures. OCN expression is
strongly upregulated in a delayed fashion in PLP cultures.
Compatible with this finding, Runx2, crucial for osteo-
blastogenesis and known to induce OCN expression
[35, 36], correlated positively with the OCN levels in
2D cultures (Fig. 2a and d). These markers appeared
before we observed a rise in calcium deposition on day
14. In therapeutic use, a maximal amount of well-
mineralized matrix is likely to be of clinical benefit. In
terms of mineral deposition, the PLP cultures appear to
have an advantage over the FCS cultures, even though
the expression of OCN seems to rise later than in FCS
cultures.
Osteogenic differentiation in the 3D collagen sponge
scaffold (Spongostan®) confirmed our findings in 2D
cultures. Similar scaffolds have been previously used in
osteogenic MSC cultures in a clinical trial treating con-
genital pseudoarthrosis in NF1 patients where healing
Fig. 7 Detection of mineralized matrix and calcium deposition in three-dimensional (3D) cell culture. Cells were cultured in 3D matrices and fixed
on day 28, mounted into Tissue-Tek and cut into 6 μm sections that were stained with Alizarin Red and photographed (a). Deposited calcium
was quantified on days 7, 14 and 21 of culture (b). DIFF differentiation, FCS fetal calf serum, PLP platelet lysate and plasma
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of bone defects and bone formation were observed [7].
However, to our knowledge, there are no previous stud-
ies with PLP-grown MSCs in collagen sponge scaffolds.
Sufficient cell proliferation is mandatory for the thera-
peutic use of MSCs and it is needed both before and after
the implantation of the cell graft. Unlike the 2D cultures,
the collagen sponge scaffold seemed to support cell prolif-
eration equally well in FCS and PLP cultures (Fig. 5a).
Consistent with ample cell proliferation, ALP activity
levels in 3D cultures were higher in PLP cultures than
FCS cultures at day 14 (Fig. 5b). However, ALP mRNA in-
creased earlier in FCS-grown than in PLP-grown MSCs
(Fig. 6b).
We also visualized the osteogenic MSC cultures and
their mineralization by staining the sponge culture
sections with Alizarin Red. We observed mineralized
nodules in both FCS and PLP cultures grown with
osteoinductive supplements (Fig. 7a). This qualitative
finding was confirmed by increased OCN mRNA copy
numbers (Fig. 6d) and increased deposited calcium
(Fig. 7b) in these cultures. Calcium levels were similar
in PLP and FCS cultures. OCN mRNA peaked on day 9
in both FCS and PLP cultures preceding the increase in
calcium level on day 14. The weakness of the current
paper is that the presence of selected osteogenic marker
proteins was not confirmed by, for example, western
blotting, which should be addressed in future studies.
Furthermore, this study was conducted in vitro, and the
findings need to be evaluated also in in-vivo assays.
In summary, both PLP and FCS appear to support the
osteogenic differentiation of MCSs, also when cultured
in 3D collagen sponge scaffold. The osteogenic markers,
however, show somewhat different temporal profiles
during the culture period. As both FCS and PLP contain
a complex mixture of different growth factors and other
biologically active molecules (hormones and so forth)
with varying and largely unknown concentrations, cer-
tain shifts in the differentiation time curve and in the
expression of specific genes could be expected. Before
executing these assays, we assumed that osteogenic dif-
ferentiation would start earlier in 2D cultures because
confluence was reached during the first few days of the
culture. Surprisingly, Runx, one of the earliest markers of
osteogenic differentiation peaked already on days 9–14 in
3D cultures, whereas 2D cultures did not show high
Runx2 levels until towards the end of the culture period
(Figs. 2a and 6a).
However, in choosing the best scaffold for repairing
bone defects, other characteristics in addition to cell pro-
liferation and differentiation are also needed, namely those
related to safety, mechanical support and resilience. Colla-
gen sponge scaffolds seem to support the MSC prolifera-
tion and differentiation during osteogenesis and have been
widely used in surgery and are thus known to be safe in
clinical practice. However, for orthopedic indications, they
may not provide enough mechanical support for repair of
large load bearing bone defects [7] and more rigid matri-
ces are required. The data and methods from this study
can be applied to further study such materials.
Although these experiments provided ample evidence
for formation of mineralized matrix during MSC culture,
higher quantities of the cells must be obtained for the
therapeutic benefit. Longer cultures, increased cell dens-
ity and addition of osteogenic growth factors may be
needed to gain sufficient amounts of bone before the
implantation [37]. Many other materials have already
been used in implantation of bone grafts and may pro-
vide better mechanical support than collagen scaffolds
used in the present experiments [27, 33, 38]. Finding the
right vector for implantation, which supports sufficient
cell proliferation both before and after the implantation,
must be further examined.
For clinical use, the most crucial points are to find a
culture method and a culture scaffold which together
support both cell proliferation and osteogenic differenti-
ation without exposing the recipient to the risk of infec-
tion and adverse host responses. Our findings suggest
that MSCs grown and differentiated in PLP, without
xenogeneic components, are a promising candidate for
regenerative medicine in treating bone defects.
Conclusions
Our data suggest that both FCS and PLP support MSC
in vitro proliferation and osteogenic differentiation. As
PLP is free of animal components and reduces the risk
of xenogeneic infections, its use for bone repair in the
clinic seems very promising. Osteogenic differentiation
is a complicated multifactorial process, where not only
soluble factors, but also the extracellular supporting
conditions are at least as important. Accordingly, in
our study MSCs differentiated in 2D and 3D conditions
showed different sensitivities to being supported by
PLP or FCS.
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